Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for

[News]

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

More... (http://www.news-medical.net/news/20140110/Synta-initiates-three-multicenter-trials-to-evaluate-ganetespib-with-chemotherapy-for-AML-and-MDS.aspx)